Identifying future research priorities using value of information analyses: Left atrial appendage occlusion devices in atrial fibrillation

Journal of the American Heart Association

Volumn 3, Issue 5, 2014, Pages

  Micieli, Andrew ^a   Bennell, Maria C ^b   Pham, Ba' ^e   Krahn, Murray ^c,d,e,f   Singh, Sheldon M ^b   Wijeysundera, Harindra C ^b,c,e,f,g  

^a UNIVERSITY OF OTTAWA   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

AGED; ARTICLE; CALCULATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; EXPECTED VALUE OF PARTIAL PERFECT INFORMATION; EXPECTED VALUE OF PERFECT INFORMATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; INFORMATION; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; MALE; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; COMPLICATION; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DEVICES; ECONOMICS; EQUIPMENT DESIGN; HEALTH CARE COST; HEART ATRIUM APPENDAGE; HEART SURGERY; PATHOPHYSIOLOGY; STATISTICAL MODEL; STROKE; TREATMENT OUTCOME; UNCERTAINTY;

AGED; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CARDIAC SURGICAL PROCEDURES; COMPARATIVE EFFECTIVENESS RESEARCH; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DABIGATRAN; DECISION SUPPORT TECHNIQUES; DRUG COSTS; EQUIPMENT DESIGN; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; MODELS, ECONOMIC; MODELS, STATISTICAL; PROBABILITY; QUALITY-ADJUSTED LIFE YEARS; STROKE; TREATMENT OUTCOME; UNCERTAINTY; WARFARIN;

EID: 84935898822     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001031     Document Type: Article

References (25)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. United States Patent and Trademark Office. USPTO patent full-text and image database [online]. 2011. Available at: http://patft. Uspto. Gov/netahtml/pto/search-adv. Htm. August 7, 2014.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; Committee R-LS, Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
4. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374:534-542.
5. Singh SM, Micieli A, Wijeysundera HC. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Circulation. 2013;127:2414-2423.
6. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32:722-732.
7. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press; 2005.
8. Briggs AH, Claxton K, Sculpher MJ. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
9. Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health. 2008;11:886-897.
10. Bojke L, Claxton K, Sculpher MJ, Palmer S. Identifying research priorities: the value of information associated with repeat screening for age-related macular degeneration. Med Decis Making. 2008;28:33-43.
11. Yokota F, Thompson KM. Value of information literature analysis: a review of applications in health risk management. Med Decis Making. 2004;24:287-298.
12. Oostenbrink JB, Al MJ, Oppe M, Rutten-van Molken MP. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health. 2008;11:1070-1080.
13. Guidelines for the Economic Evaluation of Health Technologies Canada [3rd Edition]. Ottawa: Canadian agency for drugs and technologies in health; 2009.
14. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-787.
15. Atzema CL, Austin PC, Chong AS, Dorian P. Factors associated with 90-day death after emergency department discharge for atrial fibrillation. Ann Emerg Med. 2013;61:539-548.e531.
16. Atzema CL, Austin PC, Miller E, Chong AS, Yun L, Dorian P. A population-based description of atrial fibrillation in the emergency department, 2002 to 2010. Ann Emerg Med. 2013;62:570-577.e7.
17. Atzema CL, Dorian P, Ivers NM, Chong AS, Austin PC. Evaluating early repeat emergency department use in patients with atrial fibrillation: a population-based analysis. Am Heart J. 2013;165:939-948.
18. Atzema CL, Lam K, Young C, Kester-Greene N. Patients with atrial fibrillation and an alternative primary diagnosis in the emergency department: a description of their characteristics and outcomes. Acad Emerg Med. 2013;20:193-199.
19. Larsen TB, Lip GY, Skjoth F, Due KM, Overvad K, Hvilsted Rasmussen L. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health Cohort Study. Circ Cardiovasc Qual Outcomes. 2012;5:335-342.
20. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
21. Groot Koerkamp B, Nikken JJ, Oei EH, Ginai AZ, Huniik MG. Value of information analysis used to determine the necessity of additional research: MR imaging in acute knee trauma as an example. Radiology. 2008;245:420-425.
22. Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Med Decis Making. 2004;24:207-227.
23. Janssen MP, Koffijberg H. Enhancing value of information analyses. Value Health. 2009;12:935-941.
24. McKay MD, Beckman RJ, Conover WJ. Comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics. 1979;21:239-245.
25. Diwekar UM, Kalagnanam JR. Efficient sampling technique for optimization under uncertainty. AIChE J. 1997;43:440-447.